PBAC's latest decision on Daunorubicin with cytarabine: Recommended with restriction (2023). Considered for Treatment of newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or acute myeloid leukaemia with myelodysplasia-related changes (AML-MRC) in adults.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
$75k/QALY
Range: $55k/QALY–$75k/QALY
Submissions
1
first 2023
Submissions
1
2023 → 2023
Eligible population
Adults with newly diagnosed therapy-related acute myeloid leukaemia or acute myeloid leukaemia with myelodysplasia-related changes, without prior chemotherapy for induction, excluding FLT3 mutation positive patients and those with favourable risk cytogenetics.